TCF7 and breast cancer: In vitro and in vivo analyses revealed that synthetic miR159, when used to transfect BC cell lines or administered to xenograft mouse models, was able to reduce TCF7 levels and consequently, its downstream target, c-MYC [82] (Figure 2).